Hodgkin Lymphoma (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma – Drugs In Development, 2021, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 50, 39, 2, 17, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 4, 3, 3 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).

– The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

ADC Therapeutics SA

Affimed GmbH

Akeso Inc

Alfasigma SpA

Alpine Immune Sciences Inc

Angiocrine Bioscience Inc

Anhui Anke Biotechnology (Group) Co Ltd

Apollomics Inc

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Avipep Pty Ltd

Bayer AG

BeiGene Ltd

Bio-Path Holdings Inc

Biohaven Pharmaceutical Holding Company Ltd

Bristol-Myers Squibb Co

Carrick Therapeutics Ltd

Catalent Inc

Celldex Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Hodgkin Lymphoma - Overview

Hodgkin Lymphoma - Therapeutics Development

Hodgkin Lymphoma - Therapeutics Assessment

Hodgkin Lymphoma - Companies Involved in Therapeutics Development

Hodgkin Lymphoma - Drug Profiles

Hodgkin Lymphoma - Dormant Projects

Hodgkin Lymphoma - Discontinued Products

Hodgkin Lymphoma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AbbVie Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ADC Therapeutics SA, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Affimed GmbH, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Akeso Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alfasigma SpA, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alpine Immune Sciences Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Angiocrine Bioscience Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Apollomics Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Astellas Pharma Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AstraZeneca Plc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Aurigene Discovery Technologies Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Avipep Pty Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bayer AG, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by BeiGene Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bio-Path Holdings Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bristol-Myers Squibb Co, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Carrick Therapeutics Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Catalent Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celldex Therapeutics Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectar Biosciences Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectis SA, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celleron Therapeutics Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellestia Biotech AG, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellular Biomedicine Group Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celularity Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkmate Pharmaceuticals Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkpoint Therapeutics Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CSL Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CStone Pharmaceuticals Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Curis Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Daiichi Sankyo Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Dragonfly Therapeutics Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Dyadic International Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by PlantForm Corp, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Protheragen Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rafael Pharmaceuticals Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by RAPT Therapeutics Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rhizen Pharmaceuticals SA, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rich Pharmaceuticals Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Seagen Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shattuck Labs Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by SpecificiT Pharma Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Suzhou Everhealth Biomedical Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tacitus Therapeutics Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tessa Therapeutics Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tevogen Bio Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Trillium Therapeutics Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tubulis GmbH, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tyme Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Vincerx Pharma Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Viracta Therapeutics Inc, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2021

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2021 (Contd..1)

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2021 (Contd..2)

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2021 (Contd..3)

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2021 (Contd..4)

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports